Investigational BPH drug shows no adverse events in phase II study

A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria